Cardiovascular disorder

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
2 Unique IMPs
2 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
V Various (ATC V) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase III: 3 Phase I: 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

3 trials
  • Janssen - Cilag International Commercial
    MILVEXIAN
    2022-501176-26-00 22 countries 2023 n=5,906
    Ended
  • Assistance Publique Hopitaux De Paris Academic
    PROTAMINE SULFATE
    2023-504511-32-00 1 country 2025 n=940
    Recruiting
  • Assistance Publique Hopitaux De Paris Academic
    PROTAMINE SULFATE
    2023-504511-32-00 1 country 2025 n=940
    Recruiting

Phase I

1 trial
  • Novo Nordisk A/S Commercial
    IMP not specified
    2024-519478-38-00 1 country 2025 n=116
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Assistance Publique Hopitaux De Paris Academic 2 Phase III 2
Novo Nordisk A/S Commercial 1 Phase I 0
Janssen - Cilag International Commercial 1 Phase III 0
New trials by year
2023
1
2025
3
← All indication landscapes